News

Filter

Current filters:

ridaforolimus

1 to 9 of 10 results

Merck & Co pulls EU marketing application for ridaforolimus

30-11-2012

US drug giant Merck & Co (NYSE: MRK) says it has formally notified the European Medicines Agency of its…

EuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

FDA calls for more trials on Merck & Co and Ariad's sarcoma drug ridaforolimus

06-06-2012

US drug giant Merck & Co (NYSE: MRK) has received a complete response letter from the US Food and Drug…

Ariad PharmaceuticalsMerck & CoNorth AmericaOncologyPharmaceuticalRegulationridaforolimusTaltorvic

Thumbs down for Merck & Co and Ariad sarcoma drug Taltorvic from FDA advisory

21-03-2012

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) yesterday voted by 13 to…

Ariad PharmaceuticalsMerck & CoNorth AmericaOncologyPharmaceuticalRegulationridaforolimusTaltorvic

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA

02-08-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in…

Ariad PharmaceuticalsAstraZenecaAxanumCardio-vascularEuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

More highlights from ASCO

07-06-2011

The ongoing annual meeting of the American Society of Clinical Oncology (ASCO) saw another batch of good…

Ariad PharmaceuticalsAstellas PharmaMedivationMerck & CoOncologyPharmaceuticalponatinibResearchridaforolimus

ARIAD rises on decision to co-promote ridaforolimus with Merck & Co on US approval

21-03-2011

ARIAD Pharmaceuticals (Nasdaq: ARIA) saw its shares jump 5.5% to $5.93 when it revealed that it has opted…

Ariad PharmaceuticalsLicensingMarkets & MarketingMerck & CoNorth AmericaOncologyPharmaceuticalponatinibridaforolimus

Ariad Pharma/Merck & Co’s ridaforolimus meets Ph III primary endpoint

19-01-2011

Shares of US drug developer Ariad Pharmaceuticals (Nasdaq: ARIA) rocketed 36% to $7.16 in pre-market…

Ariad PharmaceuticalsMerck & CoOncologyPharmaceuticalResearchridaforolimus

Ariad and GTx both see their share price plunge, each after updating on cancer drug clinical trials

27-05-2010

Ariad Pharmaceutical’s shares fell 8.7% to $3.58 on the news on May 25 that the independent Data…

Ariad PharmaceuticalsGTxOncologyPharmaceuticalResearchridaforolimusToremifene

1 to 9 of 10 results

Back to top